[Skip to Content]
[Skip to Content Landing]
March 1973

Single-Agent Therapy for Hodgkin's Disease

Author Affiliations

Bethesda, Md

From the National Cancer Institute, Bethesda, Md.

Arch Intern Med. 1973;131(3):377-387. doi:10.1001/archinte.1973.00320090067007

We have reviewed existing data on single drugs in the chemotherapy of Hodgkin's disease in order to place in perspective the recent results with regimens employing combinations of drugs. Combination chemotherapy, by historical comparison with single-drug therapy, is clearly superior in the induction of complete remission of disease. However, many single agents, particularly those in the antimetabolite and antibiotic classes of antitumor drugs, have been evaluated only minimally and may yet play important roles in the design of future combination therapies.